These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 22585860)
1. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. McKie AB; Vaughan S; Zanini E; Okon IS; Louis L; de Sousa C; Greene MI; Wang Q; Agarwal R; Shaposhnikov D; Wong JL; Gungor H; Janczar S; El-Bahrawy M; Lam EW; Chayen NE; Gabra H Cancer Discov; 2012 Feb; 2(2):156-71. PubMed ID: 22585860 [TBL] [Abstract][Full Text] [Related]
2. New roles opined for OPCML. Wu SY; Sood AK Cancer Discov; 2012 Feb; 2(2):115-6. PubMed ID: 22585855 [TBL] [Abstract][Full Text] [Related]
3. The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Zanini E; Louis LS; Antony J; Karali E; Okon IS; McKie AB; Vaughan S; El-Bahrawy M; Stebbing J; Recchi C; Gabra H Mol Cancer Ther; 2017 Oct; 16(10):2246-2256. PubMed ID: 28775148 [TBL] [Abstract][Full Text] [Related]
4. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Sellar GC; Watt KP; Rabiasz GJ; Stronach EA; Li L; Miller EP; Massie CE; Miller J; Contreras-Moreira B; Scott D; Brown I; Williams AR; Bates PA; Smyth JF; Gabra H Nat Genet; 2003 Jul; 34(3):337-43. PubMed ID: 12819783 [TBL] [Abstract][Full Text] [Related]
5. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679 [TBL] [Abstract][Full Text] [Related]
6. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival. Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526 [TBL] [Abstract][Full Text] [Related]
7. Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. Antony J; Zanini E; Birtley JR; Gabra H; Recchi C Cancer Gene Ther; 2021 Feb; 28(1-2):18-26. PubMed ID: 32595215 [TBL] [Abstract][Full Text] [Related]
8. Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. Birtley JR; Alomary M; Zanini E; Antony J; Maben Z; Weaver GC; Von Arx C; Mura M; Marinho AT; Lu H; Morecroft EVN; Karali E; Chayen NE; Tate EW; Jurewicz M; Stern LJ; Recchi C; Gabra H Nat Commun; 2019 Jul; 10(1):3134. PubMed ID: 31316070 [TBL] [Abstract][Full Text] [Related]
9. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells]. Yao DS; Li L; Garson K; Vanderhyden BC Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):333-8. PubMed ID: 16762191 [TBL] [Abstract][Full Text] [Related]
10. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564 [TBL] [Abstract][Full Text] [Related]
11. RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. Mei FC; Young TW; Liu J; Cheng X FASEB J; 2006 Mar; 20(3):497-9. PubMed ID: 16384911 [TBL] [Abstract][Full Text] [Related]
12. Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer. Lian B; Li H; Liu Y; Chai D; Gao Y; Zhang Y; Zhou J; Li J Breast Cancer; 2021 Mar; 28(2):448-458. PubMed ID: 33108608 [TBL] [Abstract][Full Text] [Related]
14. Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer. Xing X; Cai W; Ma S; Wang Y; Shi H; Li M; Jiao J; Yang Y; Liu L; Zhang X; Chen M BMC Cancer; 2017 Apr; 17(1):268. PubMed ID: 28407749 [TBL] [Abstract][Full Text] [Related]
15. LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer. Chao TK; Yo YT; Liao YP; Wang YC; Su PH; Huang TS; Lai HC Gynecol Oncol; 2013 Mar; 128(3):475-82. PubMed ID: 23270808 [TBL] [Abstract][Full Text] [Related]
16. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer. Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226 [TBL] [Abstract][Full Text] [Related]
17. [Effects of WWOX gene transfection on cell growth of epithelial ovarian cancer]. Yan HC; Xue JQ; Lu XY; Wan MR; Feng X; Liu XY Zhonghua Fu Chan Ke Za Zhi; 2008 May; 43(5):361-5. PubMed ID: 18953870 [TBL] [Abstract][Full Text] [Related]
18. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer. Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813 [TBL] [Abstract][Full Text] [Related]
19. OPCML: A Promising Biomarker and Therapeutic Avenue. Simovic I; Castaño-Rodríguez N; Kaakoush NO Trends Cancer; 2019 Aug; 5(8):463-466. PubMed ID: 31421903 [TBL] [Abstract][Full Text] [Related]
20. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Wang ZQ; Bachvarova M; Morin C; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Bachvarov D Oncotarget; 2014 Jan; 5(2):544-60. PubMed ID: 24504219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]